Pfizer drops Exubera

December 2007
Pharmaceutical Representative;Dec2007, Vol. 37 Issue 12, p16
The article reports that Pfizer Inc., a New York-based company, has discontinued its production of the inhaled insulin product Exubera. The Exubera inhalation powder was approved for distribution in January 2006 for the control of hyperglycemia in patients with type two diabetes. The discontinued production was caused by the poor acceptance of patients and physicians to use the product.


Related Articles

  • No evidence of inhaled insulin-related lung cancer with AERx.  // Endocrine Today;5/25/2008, Vol. 6 Issue 9, p5 

    The article discusses a report by Aradigm Corp. suggesting that patients who received inhaled insulin using the AERx insulin Diabetes Management System (iDMS) did not develop primary lung cancer. In April 2008, a lung cancer warning was added to the labeling of the insulin inhaler of Pfizer Inc....

  • Pfizer Taking Some Hits Over 'Billion-Dollar Bong' Edwards, Jim // Brandweek;2/26/2007, Vol. 48 Issue 9, p8 

    The article discusses how Pfizer's Exubera, which is an inhaled insulin product for diabetics, failed to perform financially. Pfizer forecasted that the product would produce $2 billion in annual sales, but now few observers outside the company believe that it can reach that benchmark. Many...

  • After the Crash. Clinton, Patrick // Pharmaceutical Executive;Dec2007, Vol. 27 Issue 12, p14 

    The author reflects on the decision of Pfizer Inc. (PI) to get rid of Exubera, the company's inhaled-insulin blockbuster manque. According to the author, it is disturbing to hear that PI is giving up on Exubera. However, this decision is hardly a surprise since the public knows about the...

  • Hoechst, Pfizer strike insulin deal.  // Chemical Business;Dec98, Vol. 12 Issue 12, p104 

    Reports that Hoechst AG and Pfizer Inc. have agreed to jointly develop and sell an inhaled form of insulin. Inhaled insulin as alternative to insulin shots; Mechanism of action of the inhaled insulin; Inhaled insulin's experimental delivery system from Inhale Therapeutic Systems Inc.

  • Letters to the Editor. Hoadley, Melody; Gordon, Steven K.; Wentink, Mike // Diabetes Health;Dec2005, Vol. 14 Issue 12, p10 

    Presents letters to the editor referencing topics and articles discussed in previous issues. Reaction on the withdrawal of animal insulins from the market by Eli Lilly; Experiences of a type 1 diabetic; Eating habits of a type 2 diabetic.

  • Too Many Type 2s Postponing Insulin Shots.  // Diabetes Health;Sep2006, Vol. 15 Issue 9, p32 

    The article reports on the resistance of type 2 diabetics to insulin injections according to a study conducted by the pharmaceutical company Pfizer Inc. The study has found out that type 2 diabetics who should take insulin to improve their blood glucose control tend to avoid the injection...

  • Orally inhaled insulin for type 1 and type 2 diabetes.  // Cortlandt Forum;Aug2006, Vol. 19 Issue 8, p23 

    The article provides information about Exubera, the orally inhaled insulin, developed by Pfizer Inc. in the U.S. The drug is indicated for use by patients with type 1 and type 2 diabetes. Exubera is a dry powder form of human insulin that is self-administered using its inhaler. Adverse reactions...

  • Sitaxentan voluntarily withdrawn worldwide.  // Reactions Weekly;12/18/2010, Issue 1332, p2 

    The article reports on the voluntary withdrawal of sitaxentan by Pfizer in December 2010 due to possible life-threatening risk of liver injury.

  • YOUR DRUG WAS DISCONTINUED. Weil, Andrew // Time;5/8/2006, Vol. 167 Issue 19, p195 

    The article discusses what people with diabetes should do if drug manufacturers discontinue their drugs. This issue is especially important as drug companies have stopped offering animal insulin and shifted completely to synthetically created insulin. The problem is that not all people can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics